T he FDA approved doxecitine and doxribtimine powder (Kygevvi) for thymidine kinase 2 deficiency (TK2d), an ultra-rare ...

In October 2025, the U.S. Food and Drug Administration (FDA) granted approval to multiple new cancer therapies and supportive ...

There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle ...

Elinzanetant belongs to a new class of drugs designed to target what is believed to be a key mechanism responsible for ...

UCB has scored an FDA approval for ultra-rare disease treatment Kygevvi, continuing the positive momentum for the Belgian ...

FDA approves cancer drug belantamab mafodotin-blmf for relapsed multiple myeloma in combination with bortezomib and dexamethasone.

The US Food and Drug Administration has approved another once-a-day pill that works without hormones to treat moderate to severe hot flashes in menopausal women, drugmaker Bayer said Friday.

The Food and Drug Administration has approved a new non-hormonal pill to treat hot flashes and night sweats brought on by ...

The federal Food and Drug Administration today approved a new menopause drug that reduces hot flashes and night sweats after ...

The FDA approved an intravenous (IV) formulation of fosfomycin (Contepo) to treat adults with complicated urinary tract ...

George Tidmarsh, the newly installed director of the FDA’s Center for Drug Evaluation and Research, was placed on leave ...